title: Proteomic analysis of pancreatic ductal carcinoma cells treated with 5-aza-2'-deoxycytidine.
abstract: A pancreatic adenocarcinoma cell line (PaCa44), which contains, among other alterations, a methylated p16 promoter, was treated with a chemoterapeutic agent, 5-aza-2'-deoxycytidine (DAC), in order to evaluate the effect of this drug on cell growth and protein expression. Cell proliferation was strongly inhibited by a 24 h DAC treatment and this inhibition lasted for at least 10 days. Master maps of control and treated PaCa44 cells were generated by analysis with the PDQuest software. The comparison between such maps showed up- and downregulation of 45 polypeptide chains, of which 32 were downregulated and 13 upregulated, out of a total of 700 spots detected by a medium-sensitivity stain, micellar Coomassie Brilliant Blue. Fingerprinting by mass spectrometry analysis enabled the identification of 36 of these spots. Among the major changes in DAC-treated cells: cofilin and profilin 1 are silenced; coactosin, peptidyl-propyl cis-trans isomerase A and cystatin B are decreased by 22, 16- and 15-fold, respectively; stress-70 protein, superoxide dismutase and protein disulfide isomerase A3 are increased by 13-, 11-, and 5-fold, respectively. The significance of some of these major changes is discussed.
authors.affiliation: Department of Agricultural and Industrial Biotechnologies, University of Verona, Verona, Italy.
authors.forename: Daniela
authors.initials: D
authors.lastname: Cecconi
authors.forename: Hubert
authors.initials: H
authors.lastname: Astner
authors.forename: Massimo
authors.initials: M
authors.lastname: Donadelli
authors.forename: Marta
authors.initials: M
authors.lastname: Palmieri
authors.forename: Edoardo
authors.initials: E
authors.lastname: Missiaglia
authors.forename: Mahmoud
authors.initials: M
authors.lastname: Hamdan
authors.forename: Aldo
authors.initials: A
authors.lastname: Scarpa
authors.forename: Pier Giorgio
authors.initials: PG
authors.lastname: Righetti
mesh_terms: D051339:Actin Depolymerizing Factors; D001374:Azacitidine / Q000031:analogs & derivatives* / Q000494:pharmacology*; D021441:Carcinoma, Pancreatic Ductal / Q000188:drug therapy / Q000378:metabolism*; D002455:Cell Division / Q000187:drug effects*; D003285:Contractile Proteins / Q000378:metabolism; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000235:genetics / Q000378:metabolism; D021984:Cyclophilin A / Q000378:metabolism; D055313:Cystatin B; D015891:Cystatins / Q000378:metabolism; D019175:DNA Methylation / Q000187:drug effects*; D000077209:Decitabine; D006801:Humans; D013058:Mass Spectrometry; D008840:Microfilament Proteins / Q000378:metabolism; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D051304:Profilins; D011401:Promoter Regions, Genetic / Q000235:genetics; D040901:Proteomics; D012394:Rosaniline Dyes / Q000737:chemistry; D013482:Superoxide Dismutase / Q000378:metabolism; D014407:Tumor Cells, Cultured
chemical_list: D051339:Actin Depolymerizing Factors; C524994:CSTB protein, human; D003285:Contractile Proteins; D019941:Cyclin-Dependent Kinase Inhibitor p16; D015891:Cystatins; D008840:Microfilament Proteins; C495738:PFN1 protein, human; D051304:Profilins; D012394:Rosaniline Dyes; D000077209:Decitabine; D055313:Cystatin B; D013482:Superoxide Dismutase; D021984:Cyclophilin A; C004692:coomassie Brilliant Blue; D001374:Azacitidine